Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Cell Therapeutics, Inc
Femme Max 99 ans
Cell Therapeutics, Inc
MAJ Il y a 4 ans
Paclitaxel poliglumex (CT-2103)/Carboplatin vs Paclitaxel/Carboplatin for the Treatment of Chemotherapy-Naive Advanced Non-Small Cell Lung Cancer (NSCLC) in Women with Estradiol > 30 pg/ml
To compare the overall survival of patients randomized to the CT-2103/carboplatin arm to that of patients randomised to the comparator arm (paclitaxel/carboplatin).
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme Max 99 ans
Cell Therapeutics, Inc
MAJ Il y a 6 ans
Paclitaxel Poliglumex (CT-2103) vs Paclitaxel for the Treatment of Women with Chemotherapy-Naïve Advanced Non-Small Cell Lung Cancer (NSCLC) who are Performance Status 2
The primary objective of this study is to compare the overall survival of female patients randomized to CT-2103 to that of female patients randomized to paclitaxel.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Cell Therapeutics, Inc
MAJ Il y a 4 ans
A study comparing current standard therapies with pacritinib taken by mouth for the treatment of myelofibrosis (either diagnosed alone or after polycythemia vera or essential thrombocytopenia) in patients with a low platelet count
The primary objective is to compare the efficacy of two dose-schedule arm(s) of pacritinib (pooled once daily [QD] and twice-daily [BID] dosing arms) with that of best available therapy (BAT) in patie...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations